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Background: Exercise is an essential component of contemporary cardiac rehabilitation programs for the
secondary prevention of coronary heart disease. Despite the benefits associated with regular exercise, adherence
with supervised exercise-based cardiac rehabilitation remains low. Increasingly powerful mobile technologies,
such as smartphones and wireless physiological sensors, may extend the capability of exercise-based cardiac
rehabilitation by enabling real-time exercise monitoring for those with coronary heart disease. This study compares
the effectiveness of technology-assisted, home-based, remote monitored exercise-based cardiac rehabilitation
(REMOTE) to standard supervised exercise-based cardiac rehabilitation in New Zealand adults with a diagnosis of
coronary heart disease.
Methods/Design: A two-arm, parallel, non-inferiority, randomised controlled trial will be conducted at two sites
in New Zealand. One hundred and sixty two participants will be randomised at a 1:1 ratio to receive a 12-week
program of technology-assisted, home-based, remote monitored exercise-based cardiac rehabilitation (intervention),
or an 8-12 program of standard supervised exercise-based cardiac rehabilitation (control).
The primary outcome is post-treatment maximal oxygen uptake (V̇O2max). Secondary outcomes include cardiovascular
risk factors (blood lipid and glucose concentrations, blood pressure, anthropometry), self-efficacy, intentions
and motivation to be active, objectively measured physical activity, self-reported leisure time exercise and
health-related quality of life. Cost information will also be collected to compare the two modes of delivery. All
outcomes are assessed at baseline, post-treatment, and 6 months, except for V̇O2max, blood lipid and glucose
concentrations, which are assessed at baseline and post-treatment only.
Discussion: This novel study will compare the effectiveness of technology-supported exercise-based cardiac
rehabilitation to a traditional supervised approach. If the REMOTE program proves to be as effective as traditional
cardiac rehabilitation, it has potential to augment current practice by increasing access for those who cannot
utilise existing services.
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Cardiovascular diseases (CVD) are the leading cause of
death worldwide - 30% (16.7 million) of total deaths glo-
bally [1]. The largest proportion of CVD mortality is
attributed to coronary heart disease (CHD) [2,3], the
prevalence of which is projected to increase 16.6% by
2030 [4]. Thus there is an increasing need for secondary
prevention strategies to reduce the impact of CHD. Car-
diac rehabilitation (CR) is a complex secondary prevention
intervention that aims to optimise cardiovascular disease
risk reduction, promote the adoption and adherence of
healthy behaviours and reduce disability among those with
established CHD [5]. Secondary prevention guidelines rec-
ommend a multifaceted CHD risk management approach
[6-8]; however exercise is consistently identified as an in-
tegral component of CR [5,9-11], and its potential as a risk
modification strategy extends beyond the effects of phys-
ical inactivity alone.
Numerous beneficial cardiovascular and metabolic ad-
aptations enable exercise to concurrently target several
established CHD risk factors including blood pressure,
blood lipid profile, glucose metabolism, weight status
and body composition [12]. Moreover, a Cochrane review
[13] reported 13% (RR = 0.87, 95% CI 0.75, 0.99) and 26%
(RR = 0.74, 95% CI 0.63, 0.87) reductions in all-cause and
cardiovascular mortality, respectively, following exercise-
only CR and comprehensive CR incorporating an exercise
component. These findings are supported by several other
meta-analyses [14-16].
Despite its documented benefits CR adoption is low in
many countries [9,17,18], including New Zealand [19,20].
Exercise adherence is also poor, with up to 36% attrition
from supervised programs [21-24]. Factors commonly
associated with sub-optimal participation include ill
health, domestic responsibilities, and difficulty acces-
sing supervised programs [25,26]. Low accessibility is
of particular concern as it is associated with higher
levels of cardiac morbidity and mortality [27]. A re-
cent HEART journal editorial [28] concluded that CR
should not only focus on CHD risk factor modifica-
tion and medication adherence but should also offer a
range of different delivery options for people accord-
ing to their preferences and needs to address the low
levels of participation. One such approach that has
been investigated for risk factor modification has been
the use of telehealth, which involves telephone, inter-
net, and videoconference communication between pa-
tient and health-care provider.
A systematic review of 11 telehealth trials (n = 3145)
showed significant improvements on CHD risk factors in-
cluding exercise adherence and volume, total cholesterol,
high density lipoprotein cholesterol and systolic blood
pressure [29]. While these findings support telehealth,
research has been limited to land-based telephone, internetand videoconferencing technologies that confine partici-
pants to fixed locations. As such there is a need to explore
technologies that support increased program flexibility.
Mobile technologies, including the internet are therefore
gaining increased research attention as an alternative ap-
proach to support behaviour change, clinical improvement,
and improved social functioning [30].
Emerging evidence to date for mobile interventions
for delivering healthcare and improving disease self-
management (mHealth) is promising [30]. A number of
systematic reviews support the delivery of mobile phone
text messaging interventions [31-33] for achieving behav-
iour change across a range of behaviours and chronic con-
ditions such as diabetes and asthma.
In terms of CHD, the recently completed HEART
randomised controlled trial (n = 171) demonstrated a
mobile phone text messaging and internet intervention
was effective and cost-effective for increasing leisure
time physical activity and walking, but was not effective
for increasing maximal oxygen uptake over and above
usual care in people with CVD at 6 months [34]. Com-
pared to the usual care control group, the HEART
intervention also significantly increased participants’
health-related quality of life (physical health domain),
self-efficacy and motivation to be physically active.
Structured exit interviews conducted with those who
were randomised to the intervention showed the HEART
intervention was well received, had positive effects on par-
ticipant’s physical activity levels, and was not considered
burdensome. Most (93%) participants read all or most
of their text messages [35]. Whilst this trial demon-
strated the feasibility and effectiveness of a text messa-
ging intervention to increase physical activity levels,
improvement is needed to ensure interventions achieve
positive impacts on exercise capacity and other CVD
risk factors. Such improvements include closer exercise
monitoring to ensure participants meet the required
frequency, intensity and duration to realise beneficial
physiological adaptations.
Increasingly powerful mobile technologies, such as
smartphones and wireless physiological sensors, may ex-
tend the capability of mHealth exercise-based CR (exCR)
by enabling real-time remote exercise monitoring for
those with CVD. The feasibility of remotely monitored
exCR was recently demonstrated using a smartphone,
ECG sensor and GPS receiver [36]. A six-week remote
exCR program improved walking performance (compar-
able to traditional exCR), cardiac depression and phys-
ical health-related quality of life. Furthermore, system
usability and reliability were rated highly by participants.
These encouraging results demonstrate the feasibility of
remote exCR; however, a randomised controlled trial is re-
quired to determine the benefits and harms associated
with this approach.
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To compare the effectiveness of technology-assisted,
home-based, remotely monitored exCR (REMOTE) to
standard supervised exCR in New Zealand adults with a
diagnosis of CHD.
Hypotheses
The primary hypothesis is that the REMOTE program
will be as effective at increasing exercise capacity com-
pared to standard exCR. Secondary hypotheses are; the
REMOTE program will result in similar improvements
in other cardiovascular risk factors (blood lipid and
glucose concentration, blood pressure, anthropometry)
compared to standard exCR. The REMOTE program
will result in greater exercise adherence compared to
standard exCR.
Methods/Design
The study design is a single-blinded, two-arm, parallel,
randomised controlled non-inferiority trial. Given the
established effectiveness of supervised exCR [12] the RE-
MOTE program is unlikely to result in a substantially
greater improvement in exercise capacity; however, it’s
advantages in terms of greater reach and participant ad-
herence highlight the appropriateness of a non-inferiority
trial design. The protocol is in accord with the SPIRIT
2013 statement [37,38], and the intervention is described
according to the CONSORT-EHEALTH checklist [39].
Eligibility and recruitment
Eligible participants are adults aged 18 years or more,
with a diagnosis of CHD (angina, myocardial infarction,
percutaneous coronary intervention or coronary revas-
cularisation) within the previous six months. Participants
are current outpatients who have been clinically stable
for at least six weeks, are able to perform exercise, and
can understand and write English. A Motorola (Moto G)
smart phone is available on loan to participants in the
REMOTE group. Participants who have been admitted
to hospital with heart disease within the previous six
weeks, have terminal cancer, are contraindicated for max-
imal exercise testing, have significant exercise limitations
other than CHD, currently meet the recommendations for
regular physical activity (150 min/week moderate to vigor-
ous) [40], are currently participating in a supervised
exercise program (including exCR), have a pacemaker or
implantable cardioverter-defibrillator, or have contraindi-
cations for maximal exercise testing are excluded.
Eligible participants are identified by research nurses
or research assistants from a large metropolitan hospital
in Auckland, New Zealand (population 1.6 million) prior
to discharge, through outpatient clinics and existing da-
tabases, as well as existing community CR education
sessions. Those agreeing to participate are screened foreligibility and provided a study pack, which includes a
participant information sheet and consent form. Contact
details of interested participants are sent to the research
team. Participants identified in hospital and through out-
patient clinics are telephoned approximately one month
after discharge or one week after initial contact, respect-
ively, to confirm their interest in the study and schedule
a baseline assessment. Eligible participants are also re-
cruited by a research staff at an existing CR clinic in the
Bay of Plenty, New Zealand. These participants have
been discharged from hospital, are eligible to participate
in CR but have not yet enrolled in a program. Interested
participants are given a study pack and a baseline assess-
ment is scheduled.
Sample size calculation
The target sample size of 162 participants (81 per group)
will provide 80% power at 2.5% level of significance
(one-sided) to show that the REMOTE and standard exCR
programs do not differ by more than ml·kg-1·min−1 on peak
oxygen uptake (V̇O2max). This sample size is based on the
assumption the standard exCR program will result in an
increase of 2.4 ml·kg−1·min−1 (SD =2.7) in V̇O2max, and
has been inflated to allow for 10% loss to follow up [12].
The non-inferiority margin was chosen because it is clinic-
ally significant and is associated with lower CV-mortality
[41,42].
Ethics approval
Ethical approval for the trial was received from the
University of Auckland Human Participants Ethics
Committee (011021). Approval was also obtained from
the Metropolitan Hospital’s Research Review Board.
Randomisation and blinding
After written consent is obtained, baseline assessment is
completed and then participants are randomised using
sealed sequential, opaque envelopes. Participants are ran-
domly allocated to either the control (traditional exCR) or
intervention (REMOTE) arms at a 1:1 ratio, stratified by
study site and sex. The allocation sequence is overseen by
the project statistician (YJ). Assessors of the primary out-
comes are blind to treatment allocation; however partici-
pants are not blind.
Intervention
The REMOTE intervention is delivered over 12 weeks and
comprises a personalised exercise prescription, real-time
remote exercise monitoring, and behavioural support to
increase exercise adherence (goal setting, exercise schedul-
ing, overcoming barriers), delivered via smartphone. The
intervention aims to have individuals participate in moder-
ate to vigorous aerobic-based exercise for at least 30 mi-
nutes (preferably more), most days (≥5) of the week, in
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College of Sports Medicine (ACSM) guidelines [43]. Spe-
cific details are provided below.
Exercise prescription
An individualised exercise prescription, based on per-
sonal preferences and current exercise capacity, is a core
component of the intervention. Following ACSM guide-
lines for exercise in cardiac patients [43] participants are
provided with a weekly prescription detailing exercise
duration, frequency and intensity, via a smartphone ap-
plication (app) designed for this study. The prescribed
exercise intensity is sufficient to induce a “training ef-
fect”, yet below a metabolic load that evokes abnormal
clinical signs or symptoms. Exercise duration is increased
according to symptoms and clinical status. Exercise inten-
sity is increased gradually as tolerated [44]. Progression of
exercise prescription components occurs in the following
order: duration, frequency, then intensity [44]. Participants
are taught and encouraged to use ratings of perceived ex-
ertion (RPE) and the heart rate reserve method (HRR) to
achieve the desired intensity. During early stages the level
of intensity targets an RPE of 11 to 13 (“fairly light” and
“somewhat hard”; 6–20 scale) [45] and/or 40% to 50%
HRR. During the latter stages the level of intensity targets
an RPE of 13 to 15 (“somewhat hard” to “hard”) and/or
55% to 65% HRR. The preferred mode of exercise is walk-
ing, although participants are able to choose other modes
(e.g. cycling, rowing) if preferred.
Remote monitoring
During pre-defined time windows (e.g. 06:00–11:00) partic-
ipants connect to the remote exercise monitoring system,
which permits a remotely-located exercise physiologist to
monitor their location, distance, speed, heart rate, respira-
tory rate, training load and single-lead ECG in real-time;
provide real-time feedback and support via participants’
smartphone (including alerts, messages or telephone calls);
respond to adverse events if necessary; provide post-
exercise feedback; and modify participants’ exercise pre-
scription as required. Participants can be monitored in any
environment with an active broadband connection (mobile,
Wi-Fi, Bluetooth).
The REMOTE system, comprising a physiological sens-
ing device, smartphone and web apps, and a middleware
platform, supports simultaneous monitoring of multiple
participants. Participants are loaned a BioHarness 3
(Zephyr Technologies, USA) physiological sensing de-
vice to wear during exercise. The BioHarness enables
measurement of a comprehensive range of physiological
parameters required for monitoring exercise performance.
Bluetooth connectivity permits transmission of data to
smartphones. The system including the Zephyr device,
smartphone (Android) app, and the Odin middlewareplatform has been tested for reliability and validity
(Rawstorn J, Gant N, Warren I, Doughty R, Lever N,
Poppe K: Measurement and data transmission validity
of a multi-biosensor system for real-time remote exer-
cise monitoring among cardiac patients, forthcoming).
The Odin middleware platform is an off-the-shelf solu-
tion that provides reliable communication, minimises
data usage cost and maximises device battery life [46].
The smartphone app collects and transmits physiological
data to a remotely located web server in real-time. The
web app displays these data in remote locations, and en-
ables real-time provision of feedback to moderate partici-
pants’ exercise behaviour.
Support and strategies to facilitate exercise adherence
Messages outlining key behaviour change strategies are
sent to participants via the smartphone by the exercise
physiologist. Three messages per week are sent for the
12 week intervention period. The program is grounded
in self-efficacy theory [47,48], which is the most exam-
ined psychological variable within the cardiac setting.
Behaviour change strategies focus on increasing confi-
dence and motivation to exercise, overcoming barriers to
being physically active, scheduling exercise into daily life,
goal setting, and enhancing social support and networks
to be active. In addition, features on the smartphone app
allow participants to review their exercise performance
and assess progress toward personalised goals.
Control
The active control group receive an 8-12 week program
of supervised exercise, delivered at Auckland or Tau-
ranga CR clinics. Supervised exercise sessions are offered
two-three times per week by trained exercise scientists/
nurses. Participants typically complete a 15-minute warm
up, 30–45 minutes of moderate-vigorous intensity aerobic
exercise on various exercise modalities (e.g., treadmill,
cycle ergometer, rowing machine), and a 5 min cool down.
Heart rate, blood pressure, and rating of perceived exer-
tion (RPE) are monitored on a regular basis. Exercise pre-
scription for the control group also adheres to ACSM
guidelines for exercise in cardiac patients [43].
Outcome assessments
All assessments are conducted at the University of
Auckland and Tauranga cardiac clinics. Prior to the
baseline assessment participants are sent an accelerom-
eter to wear for seven consecutive days. Baseline assess-
ments involve an explanation of study procedures,
signed consent and collection of participant-reported
secondary outcomes, followed by physical measurements
(stature, body mass, body mass index, waist and hip cir-
cumference), blood lipid and glucose measurements, and a
test of maximal exercise capacity. The baseline assessment
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pants to the respective study groups.
The primary outcome is maximal oxygen uptake
(V̇O2max) assessed at baseline and post-treatment. An
individualised exercise testing protocol is used to assess
V̇O2max via respiratory gas analysis. A graded protocol
is initiated at a comfortable walking speed and 0% gradi-
ent. The gradient then increases by 1% every 60 seconds
until volitional exhaustion, or the presence of indications
for test termination [44]. The target exercise time is 8 to
12 minutes. Individualised walking speeds are replicated
at the 13 week follow-up assessment. Participants are
encouraged to continue the test until the respiratory ex-
change ratio (RER) exceeds 1.10, indicative of a maximal
aerobic performance. The ACSM guidelines for exercise
testing cardiac patients are adhered to [44]. Exercise test-
ing is conducted at the University of Auckland Clinics,
Tamaki Campus, and the Tauranga cardiac clinic by
trained physiologists. A medical physician is available to
deal with any emergencies that may arise.
Secondary outcomes
All secondary outcomes are assessed at baseline, post-
treatment and 6 months, except for blood lipid and glu-
cose concentrations, which are assessed at baseline and
post-treatment only. Stature, body mass, waist and hip
circumference, and blood pressure are measured using
standardised procedures. An electronic sphygmoman-
ometer will be used to assess systolic and diastolic pres-
sure after at least 5 minutes of seated rest. Participants’
height will be measured to the nearest 0.1 cm using a
stadiometer, and body mass to the nearest 0.1 kilograms
using electronic scales. Body mass index is derived from
the weight (kg) divided by height (m) squared. Waist cir-
cumference is measured using an anthropometric tape
measure placed around the participant’s waist at the
level of the umbilicus. Hip circumference is measured
around the furthest protrusion of the buttocks as seen
from a lateral perspective. Waist-hip ratio is calculated
according to ISAK protocols [49].
A fingertip blood sample is obtained from participants
for analysis of blood lipid and glucose concentration using
automated point of care analysers (Cholestech LDX at the
Auckland site, CardioChek at the Tauranga site).
Psychological variables including self-efficacy (situ-
ational self-confidence), intentions, and motivation to
exercise are assessed to determine their potential medi-
ating effect. Task self-efficacy is assessed using a scale
adapted from the Self-Efficacy Scale [50]. Participants
rate their confidence to perform physical activities for
increasing periods of time (i.e., 10, 30, and 60 min) at
three intensities (i.e., light, moderate, and vigorous). A
key is provided to define these levels of intensity. Mean
scores are calculated with higher values indicatinggreater efficacy to perform physical activity for longer
duration and greater intensity.
Participants’ confidence to exercise in the face of
obstacles (barrier efficacy) is assessed using the Barriers
Efficacy Scale [50]. Participants rate their confidence to
overcome eight common reasons preventing people from
participating in exercise sessions (e.g., pain, bad weather)
on a scale ranging from 0% (no confidence at all) to 100%
(completely confident). Mean scores are calculated with
higher values indicating greater efficacy to overcome bar-
riers to exercise.
Self-efficacy to follow their exercise prescription is
assessed using 9 items. Participants rate their confidence
in their ability to follow the prescribed exercise regimen
on a scale ranging from 0% (no confidence at all) to
100% (completely confident). Mean scores are calculated
with higher values indicating greater efficacy to adhere
to prescribed exercise.
Intentions to perform physical activity are assessed
using two items [51], which ask participants to rate their
level of intention to follow their exercise prescription
during the next 3 months (e.g. “I definitely intend to
follow my exercise prescription”). The items are scored
using a seven point Likert scale ranging from 0 (com-
pletely disagree) to 7 (completely agree). A mean score
from the two items is used to give an overall measure of
intention with higher values indicating greater intention
to perform physical activity.
Self-determination to exercise is operationalised using
the Locus of Causality for Exercise Scale; a reliable and
valid three-item self-report measure of the extent to
which participants feel they choose to exercise with no
sense of coercion [52]. Participants rate how much they
agree or disagree with each statement on a seven-item
Likert scale from 1 (Strongly disagree) to 7 (Strongly
agree) indicating their motivation to perform exercise.
Mean scores are calculated with higher values indicating
greater self-determination or a more internal perceived
locus of causality.
Leisure time exercise is assessed using the Godin Leisure
Time Physical Activity Questionnaire (GLTPAQ) [53]. This
simple three-item questionnaire has well-established reli-
ability and validity and has been used in patients undergo-
ing CR (N= 826) [53].
Objective physical activity is assessed using the Acti-
graph accelerometer (www.theActigraph.com), which is
sent to participants to wear for 7 consecutive days. The
Actigraph is a small piezoelectric accelerometer and has
been validated in healthy and cardiac patients [54,55]. Raw
data are processed according to accepted procedures [56].
Adherence to the prescribed regimens is assessed by
determining the number of sessions attended compared
to the number of sessions prescribed. Participants in both
programs are encouraged to participate in supervised
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lected weekly and summed to determine total attendance
(the numerator) compared to total number of sessions
prescribed (denominator).
Cost information is collected and includes the cost of
each program and direct medical costs (including cost of
treatment, primary care, secondary care and over-the-
counter medications). The EQ5D [57] is used to obtain a
single preference index for calculation of Quality Adjusted
Life Year (QALY) to assess cost per QALY for comparison
with CR programs. Healthcare utilisation is recorded for
adverse events including cardiac events, and other events
participants deem likely to be related to their participa-
tion in the study (including, but not limited to, muscu-
loskeletal injury).Statistical analysis
Statistical analyses will be performed using SAS version
9.2 (SAS Institute Inc. Cary NC) and R version 2.11 (R
Foundations for Statistical Computing). Baseline charac-
teristics will be summarised using descriptive statistics.
Continuous variables will be described as numbers of
observed and missing values, mean, standard deviation,
median, minimum and maximum. Categorical variables
will be described as frequencies and percentages. Treat-
ment evaluation will be performed on the principle of
intention to treat (ITT), using data collected from all ran-
domised participants. Analysis of covariance (ANCOVA)
regression model will be used to evaluate the main treat-
ment effect on the primary outcome between the two
treatment groups, adjusting for its baseline measure, age,
ethnicity and other potential confounding factors (if they
are statistically significant at 5% level). A similar approach
will be used for other continuous secondary outcome
measures. Logistic regression model will be considered for
the analysis of a binary outcome (e.g. meeting physical ac-
tivity recommendations).Discussion
This novel study evaluates a supervised exercise program
delivered via a mobile phone and sensor system compared
to a traditional model of supervised exCR. Remote moni-
toring may offer the same benefits as supervised gym-
based programs, but is potentially more accessible to a
broader range of patients and is cost-effective.
The protocol, in accordance with the SPIRIT state-
ment, incorporates findings from recent mobile and tele-
health systematic reviews, with the aim of building on
this empirical evidence. The REMOTE-CR trial includes
an objective assessment of maximal cardiorespiratory fit-
ness, which is the gold standard measurement following
exCR. It also includes objective assessment of physical
activity, which was lacking in previous research [34].The non-inferiority trial design is most suitable be-
cause it is unlikely the REMOTE intervention will result
in substantially greater improvement in exercise capacity
compared to traditional supervised exercise [58]. The
non-inferiority margin (V̇O2 1.25 ml·kg
−1·min−1) is clinic-
ally significant and is associated with lower cardiovascular
mortality [59].
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